Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine Stock Looks Attractive In the Wake Of A 30% Correction
10:20am, Wednesday, 16'th Dec 2020
Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for growth in the near term. NBIX stock is up just
Neurocrine Biosciences Hit By Multiple Setbacks
04:50am, Tuesday, 17'th Nov 2020
Neurocrine Biosciences reported disappointing sales of Ingrezza, as disruptions to clinical practice caused by COVID-19 have impacted new prescriptions, refills, and patient compliance. If COVID-19 is
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
12:10am, Tuesday, 10'th Nov 2020
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
Recap: Neurocrine Biosciences Q3 Earnings
04:54pm, Monday, 09'th Nov 2020
Shares of Neurocrine Biosciences (NASDAQ:NBIX) decreased 13.34% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.78% year over year to $0.9
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
09:00am, Monday, 09'th Nov 2020
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gor
Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?
11:10am, Wednesday, 04'th Nov 2020
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in
Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?
07:10am, Tuesday, 03'rd Nov 2020
Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to the S&P 500 which is up by about 2% over the same period. This theme includes he
Alexion Pharmaceuticals: More Potential Ahead Despite Upbeat Guidance (NASDAQ:ALXN)
03:23am, Wednesday, 07'th Oct 2020
Alexion’s just-released revision to 2020 revenue guidance suggests continuing top line momentum. Given the strong performance through the pandemic, we believe there is even more room for growth as m
Government considers fast-tracking National Broadband Plan
11:55am, Wednesday, 23'rd Sep 2020
Covid crisis has highlighted importance of good broadband, says minister
AbbVie: I Don't Wanna Miss This Thing (NYSE:ABBV)
12:30pm, Tuesday, 22'nd Sep 2020
2020 is shaping up to be another record year for AbbVie. Six months into the pandemic, AbbVie has mastered the crisis better than expected and once again demonstrated the power of its strong and resil
An Apple For Powell: Fed Meeting, Cupertino Event Could Dominate Today's Action
12:00am, Tuesday, 15'th Sep 2020
How does the market follow up “Merger Monday?” Today the fun rolls on with a product presentation from Apple Inc. (NASDAQ: AAPL), the start of a Fed meeting...
New Data Support The Idea That Neurocrine Biosciences Is Building A Credible Parkinson's Portfolio
01:41pm, Monday, 14'th Sep 2020
A clinical update on VY-AADC showed sustained improvements in on/off time and motor function, but the data don't support the idea that this is a truly game-changing therapy for Parkinson's.
Cramer's lightning round: 'I think you hold Boeing'
11:01pm, Thursday, 20'th Aug 2020
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
